![Marianna Fontana, ESC 2022: NNC6019-0001, a phase II study for transthyretin amyloid cardiomyopathy – touchCARDIO Marianna Fontana, ESC 2022: NNC6019-0001, a phase II study for transthyretin amyloid cardiomyopathy – touchCARDIO](https://www.touchcardio.com/wp-content/uploads/sites/4/2022/09/Prof-Fontana-thumbnail.jpg)
Marianna Fontana, ESC 2022: NNC6019-0001, a phase II study for transthyretin amyloid cardiomyopathy – touchCARDIO
![Montefiore Heart on Twitter: "#MonteHeart CT/CMR Lecture Series: NEXT UP➡️Multimodality Imaging in Cardiac Amyloidosis with Dr Marianna Fontana on Friday Jan 8th, 2021 at 12 PM EST via @zoom_us. For zoom link, Montefiore Heart on Twitter: "#MonteHeart CT/CMR Lecture Series: NEXT UP➡️Multimodality Imaging in Cardiac Amyloidosis with Dr Marianna Fontana on Friday Jan 8th, 2021 at 12 PM EST via @zoom_us. For zoom link,](https://pbs.twimg.com/media/ErEWDtSXEAI6PrN.jpg)
Montefiore Heart on Twitter: "#MonteHeart CT/CMR Lecture Series: NEXT UP➡️Multimodality Imaging in Cardiac Amyloidosis with Dr Marianna Fontana on Friday Jan 8th, 2021 at 12 PM EST via @zoom_us. For zoom link,
![Andrew R. Houghton on Twitter: "Dr Marianna Fontana explains the value of T1 mapping in the CMR assessment of cardiac amyloidosis #BCS2017 https://t.co/dgwZy0iSp0" / Twitter Andrew R. Houghton on Twitter: "Dr Marianna Fontana explains the value of T1 mapping in the CMR assessment of cardiac amyloidosis #BCS2017 https://t.co/dgwZy0iSp0" / Twitter](https://pbs.twimg.com/media/DBtBz9yXYAAt4J2.jpg:large)